Tirzepatide, a novel medication agent, has emerged as a groundbreaking innovation in the realm of GLP-1 receptor agonism. Unlike previous GLP-1 receptor agonists, tirzepatide custom peptides exerts its effects by simultaneously activating both the GLP-1 and GIP receptors. This dual mechanism of action enhances a morerobust reduction in glucose leve